Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection

Abstract

Importance There is limited evidence regarding whether the presence of serum antibodies to SARS-CoV-2 is associated with a decreased risk of future infection. Understanding susceptibility to infection and the role of immune memory is important for identifying at-risk populations and could have implications for vaccine deployment. Objective The purpose of this study was to evaluate subsequent evidence of SARS-CoV-2 infection based on diagnostic nucleic acid amplification test (NAAT) among individuals who are antibody-positive compared with those who are antibody-negative, using real-world data. Design This was an observational descriptive cohort study. Participants The study utilized a national sample to create cohorts from a de-identified dataset composed of commercial laboratory test results, open and closed medical and pharmacy claims, electronic health records, hospital billing (chargemaster) data, and payer enrollment files from the United States. Patients were indexed as antibody-positive or antibody-negative according to their first SARS-CoV-2 antibody test recorded in the database. Patients with more than 1 antibody test on the index date where results were discordant were excluded. Main Outcomes/Measures Primary endpoints were index antibody test results and post-index diagnostic NAAT results, with infection defined as a positive diagnostic test post-index, as measured in 30-day intervals (0-30, 31-60, 61-90, >90 days). Additional measures included demographic, geographic, and clinical characteristics at the time of the index antibody test, such as recorded signs and symptoms or prior evidence of COVID-19 (diagnoses or NAAT+) and recorded comorbidities. Results We included 3,257,478 unique patients with an index antibody test. Of these, 2,876,773 (88.3%) had a negative index antibody result, 378,606 (11.6%) had a positive index antibody result, and 2,099 (0.1%) had an inconclusive index antibody result. Patients with a negative antibody test were somewhat older at index than those with a positive result (mean of 48 versus 44 years). A fraction (18.4%) of individuals who were initially seropositive converted to seronegative over the follow up period. During the follow-up periods, the ratio (CI) of positive NAAT results among individuals who had a positive antibody test at index versus those with a negative antibody test at index was 2.85 (2.73 - 2.97) at 0-30 days, 0.67 (0.6 - 0.74) at 31-60 days, 0.29 (0.24 - 0.35) at 61-90 days), and 0.10 (0.05 - 0.19) at >90 days. Conclusions Patients who display positive antibody tests are initially more likely to have a positive NAAT, consistent with prolonged RNA shedding, but over time become markedly less likely to have a positive NAAT. This result suggests seropositivity using commercially available assays is associated with protection from infection. The duration of protection is unknown and may wane over time; this parameter will need to be addressed in a study with extended duration of follow up.

Full text

Its licence does not allow us to show the full text. Read it at PubMed Central:

References 33

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1038/s41586-020-2912-6

2. 2.
   Robust neutralizing antibodies to SARS-CoV-2 infection persist for months · 2020

   No notice
3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1056/nejmoa2026116

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1038/s41591-020-0965-6

5. 5.
   SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic · 2021

   No notice
6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1101/2020.11.01.362319

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1056/nejmc2025179

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.15585/mmwr.mm6943a4

9. 9.
   Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate · 2020

   No notice
10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/s1473-3099(20)30764-7

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/s1473-3099(20)30783-0

14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1002/jmv.26056

15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1002/jmv.25952

16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.jhin.2020.09.011

17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1002/cti2.1160

18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1002/jmv.26280

19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.3389/fmed.2020.00562

20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/s2213-2600(20)30453-7

21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41420-020-00375-y

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.jcv.2020.104539

23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1001/jama.2020.8259

25. 25.
    Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison · 2020

    Corrected
26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1128/jcm.01243-20

27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1056/nejmoa2034577

30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1002/pds.5029

31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1136/openhrt-2018-000788

32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.jval.2017.03.008

33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1002/cpt.946

Cited by papers we hold 3

• Infection induced SARS-CoV-2 seroprevalence and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain · 2021
  Not checked
• Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer · 2021
  No notice
• Assessment of SARS-CoV-2 Reinfection 1 Year After Primary Infection in a Population in Lombardy, Italy · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.